|
| Study | Design | Treatment groups | Disease | G-CSF treatment schedule | Conclusion | Effect of G-CSF |
|
|
Garg et al., 2012 [10] | Effect of G-CSF on survival rate in patients with liver failure | Placebo
G-CSF | Acute-on-chronic liver disease | 5 μg/kg | G-CSF decreased risk of sepsis significantly | Positive |
|
|
Stephens et al. [26] | Effect of G-CSF on patients with septic shock | Placebo
G-CSF | Septic shock | 263 μg/day, 3 days | G-CSF did not improve outcome in patients with septic shock | Indifferent |
|
|
Cheng et al., 2007 [25] | Effect of G-CSF on severe septic patients with melioidosis infection | Placebo
G-CSF | Melioidosis | 263 μg/day, 3 days | G-CSF was associated with a longer duration of survival but was not associated with a higher survival rate | Indifferent |
|
|
Hartmann et al., 2005 [24] | Effect of G-CSF on pneumonia patients | Placebo
G-CSF | Nosocomial pneumonia | 300–480 μg/day for 7 days | G-CSF decreased risk of sepsis but did reach significance | Indifferent |
|
|
Hartung et al., 2003 [55] | Perioperative treatment of G-CSF before abdominal surgery | Placebo
G-CSF | Mixture, operation | 5 μg/kg for 3 times or continuous administration of 5 μg/kg for 5 days after an initial bolus of 5 μg/kg | G-CSF decreased the postoperative infection | Positive |
|
|
Root et al., 2003 [23] | Effect of G-CSF on pneumonia and sepsis patients | Placebo
G-CSF | Pneumonia and severe sepsis | 300 μg/day for 5 days | G-CSF was not efficacious in reducing mortality and complications from infection | Indifferent |
|
|
Tanaka et al., 2001 [56] | Lung injury was investigated after G-CSF treatment | Placebo
G-CSF | Sepsis | 2 μg/kg for 5 days | G-CSF attenuated inflammatory response | Positive |
|
|
Ishikawa et al., 2000 [8] | G-CSF with relative neutropenia septic patients | Absolute neutrophil count: high, moderate, and low | Mixture | 2 μg/kg for 5 days | G-CSF was effective in septic patient with a percentage of immature neutrophils, but less effect with high percentage of immature neutrophils and bone marrow was depressed. | Positive |
|
|
Nelson et al., 1998 [22] | Effect of G-CSF on pneumonia patients | Placebo
G-CSF | Community-acquired pneumonia | 300 μg/day for 10 days | G-CSF did increase neutrophil levels but did not affect the mortality of patient with pneumonia | Indifferent |
|
